Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4alpha,5-epoxy-17beta-hydroxy-3-oxoandrostane-2-carbonitrile
2. Modrenal
3. Win 24,540
1. 13647-35-3
2. Modrenal
3. Vetoryl
4. Desopan
5. Modrastane
6. Trilostanum
7. Trilostano
8. Win-24540
9. Win 24,540
10. Chebi:32260
11. L0fpv48q5r
12. Win 24540
13. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4alpha,5alpha,17beta)-
14. Nsc-758904
15. Dsstox_cid_3706
16. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4a,5a,17b)-
17. Dsstox_rid_77157
18. Dsstox_gsid_23706
19. (1ar,4ar,4bs,6as,7s,9as,9bs,11as)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile
20. (1s,2r,6r,8s,11s,12s,15s,16s)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.0^{2,8}.0^{6,8}.0^{12,16}]octadec-4-ene-4-carbonitrile
21. Modrenal (tn)
22. (1ar,4ar,4bs,6as,7s,9as,9bs,11as)-2,7-dihydroxy-4a,6a-dimethyl-1a,4,4a,4b,5,6,6a,7,8,9,9a,9b,10,11-tetradecahydrocyclopenta[7,8]phenanthro[1,10a-b]oxirene-3-carbonitrile.
23. (1s,2r,6r,8s,11s,12s,15s,16s)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
24. Desopan (tn)
25. Cas-13647-35-3
26. Trilostane (jan/usan)
27. Trilostanum [inn-latin]
28. Trilostano [inn-spanish]
29. Unii-l0fpv48q5r
30. Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4.alpha.,5.alpha.,17.beta.)-
31. Trilostane [usan:inn:ban:jan]
32. Ncgc00274061-01
33. Einecs 237-133-0
34. Mfcd00199295
35. Win 24450
36. Trilostane [mi]
37. Trilostane [inn]
38. Trilostane [jan]
39. Trilostane [usan]
40. Trilostane [vandf]
41. (4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
42. Schembl7517
43. Trilostane [mart.]
44. Trilostane [who-dd]
45. Gtpl6850
46. Trilostane [green Book]
47. Chembl1200907
48. Dtxsid9023706
49. Trilostane [orange Book]
50. Trilostane, >=98% (hplc)
51. 4.alpha.,5-epoxy-3,17.beta.-dihydroxy-5.alpha.-androst-2-ene-2-carbonitrile
52. Hms3884a15
53. Bcp04132
54. Tox21_112454
55. Tox21_302406
56. 4-alpha,5-epoxy-3,17-dihydroxy-5-alpha-androst-2-ene-2-carbonitrile
57. Ac-927
58. Bdbm50247882
59. S1404
60. 3,17beta-dihydroxy-4alpha,5-epoxy-5alpha-androst-2-ene-2-carbonitrile
61. 4alpha,5-epoxy-3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile
62. Akos015964043
63. Akos032947221
64. Tox21_112454_1
65. Zinc100038546
66. Ccg-267803
67. Cs-1707
68. Db01108
69. Ks-1414
70. Nsc 758904
71. (2-alpha,4-alpha,5-alpha,17-beta)-4,5-epoxy-17-hydroxy-3-oxoandrostane-2-carbonitrile
72. 4-alpha-5-epoxy-17-beta-hydroxy-3-oxo-5-alpha-androstane-2-alpha-carbonitrile
73. Androstane-2-carbonitrile, 4,5-epoxy-17-hydroxy-3-oxo-, (2-alpha,4-alpha,5-alpha,17-beta)-
74. Ncgc00255201-01
75. Hy-14281
76. Bcp0726000098
77. D01180
78. Ab01274788-01
79. Ab01274788_02
80. 647t353
81. A886681
82. Q907313
83. Q-201884
84. Z1563146079
85. Trilostane; 13647-35-3; Vetoryl; Modrenal; Modrastane
86. (4a,5a,17b)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile
87. 5-alpha-androstane-2-alpha-carbonitrile, 4-alpha,5-epoxy-17-beta-hydroxy-3-oxo-
Molecular Weight | 329.4 g/mol |
---|---|
Molecular Formula | C20H27NO3 |
XLogP3 | 2.9 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 0 |
Exact Mass | 329.19909372 g/mol |
Monoisotopic Mass | 329.19909372 g/mol |
Topological Polar Surface Area | 76.8 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 692 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 8 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Used in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
Trilostane blocks an enzyme involved in the production of several steroids including cortisol. Inhibiting this enzyme inhibits the production of cortisol. In Cushing's syndrome, the adrenal gland overproduces steroids. Although steroids are important for various functions of the body, too much can cause problems. Trilostane reduces the amount of steroids produced by the adrenal gland. This product was withdrawn from the U.S. market in April 1994.
Abortifacient Agents, Steroidal
Steroidal compounds with abortifacient activity. (See all compounds classified as Abortifacient Agents, Steroidal.)
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
H - Systemic hormonal preparations, excl. sex hormones and insulins
H02 - Corticosteroids for systemic use
H02C - Antiadrenal preparations
H02CA - Anticorticosteroids
H02CA01 - Trilostane
Hepatic.
8 hours.
Trilostane produces suppression of the adrenal cortex by inhibiting enzymatic conversion of steroids by 3-beta-hydroxysteroid dehydrogenase/delta 5,4 ketosteroid isomerase, thus blocking synthesis of adrenal steroids.
ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19686
Submission : 2006-08-14
Status : Active
Type : II
NDC Package Code : 64918-0725
Start Marketing Date : 2014-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6092
Submission : 1985-11-13
Status : Inactive
Type : II
NDC Package Code : 26251-0005
Start Marketing Date : 2019-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64958-0102
Start Marketing Date : 2024-12-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 60592-665
Start Marketing Date : 2023-10-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-2387
Start Marketing Date : 2006-01-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-5113
Start Marketing Date : 2020-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 64918-0725
Start Marketing Date : 2014-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52128-165
Start Marketing Date : 2013-03-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 26251-0005
Start Marketing Date : 2019-08-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
A Trilostane manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trilostane, including repackagers and relabelers. The FDA regulates Trilostane manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trilostane API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Trilostane manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Trilostane supplier is an individual or a company that provides Trilostane active pharmaceutical ingredient (API) or Trilostane finished formulations upon request. The Trilostane suppliers may include Trilostane API manufacturers, exporters, distributors and traders.
click here to find a list of Trilostane suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Trilostane DMF (Drug Master File) is a document detailing the whole manufacturing process of Trilostane active pharmaceutical ingredient (API) in detail. Different forms of Trilostane DMFs exist exist since differing nations have different regulations, such as Trilostane USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Trilostane DMF submitted to regulatory agencies in the US is known as a USDMF. Trilostane USDMF includes data on Trilostane's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Trilostane USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Trilostane suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Trilostane as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Trilostane API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Trilostane as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Trilostane and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Trilostane NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Trilostane suppliers with NDC on PharmaCompass.
Trilostane Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trilostane GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trilostane GMP manufacturer or Trilostane GMP API supplier for your needs.
A Trilostane CoA (Certificate of Analysis) is a formal document that attests to Trilostane's compliance with Trilostane specifications and serves as a tool for batch-level quality control.
Trilostane CoA mostly includes findings from lab analyses of a specific batch. For each Trilostane CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trilostane may be tested according to a variety of international standards, such as European Pharmacopoeia (Trilostane EP), Trilostane JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trilostane USP).
LOOKING FOR A SUPPLIER?